top of page
The EVOLUTION Trial for Psoriatic Arthritis is being conducted at several centers across the United States.
The purpose of the study is to determine the most effective treatment for people with psoriatic arthritis (PsA) who have either stopped responding to or didn't respond to a TNFi (Tumor Necrosis Factor inhibitor) such as Humira, Enbrel, Cimzia or Remicade. Specifically, we are studying whether, after loss of response or lack of response to a TNFi, switching to an IL23i (Interleukin-23 inhibitor) is more effective than switching to a different TNFi.
INTERESTED?
Please complete this contact form!
Someone on our study team will follow up with you as soon as possible!
bottom of page